Circulating Biomarkers

被引：31

作者：

Badimon, L. ^{[1
,2
,3
]}

Romero, J. C. ^{[1
]}

Cubedo, J. ^{[1
]}

Borrell-Pages, M. ^{[1
]}

机构：

[1] Hosp Santa Creu & Sant Pau, CSIC ICCC, Cardiovasc Res Ctr, IIB St Pau, Barcelona, Spain

[2] Inst Salud Carlos III, CIBERobn, Madrid, Spain

[3] UAB, Cardiovasc Res Chair, Barcelona, Spain

来源：

THROMBOSIS RESEARCH | 2012年 / 130卷

关键词：

cardiovascular disease; biomarker; myocardial infarction; risk factor; atherosclerosis; C-REACTIVE PROTEIN; CARDIOVASCULAR-DISEASE; RISK-FACTORS; MYELOPEROXIDASE; ADRENOMEDULLIN; INFLAMMATION; PREDICTION; ISCHEMIA; ALBUMIN; BINDING;

D O I：

10.1016/j.thromres.2012.08.262

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

Cardiovascular diseases (CVD) remain a leading cause of death worldwide. In the past years new biomarkers have drawn the clinician's attention for their use in primary prevention and in the identification of individuals at cardiovascular risk. Biomarkers also provide information on the progression and possible recurrence of cardiovascular events, and include inflammatorymarkers (C-reactive protein and interleukin-18), endothelial dysfunction markers (intercellular adhesion molecule-1 and vascular cell adhesion molecule-1), neurohormonal markers (brain natriuretic peptide and copeptine), ischemia biomarkers (apolipoprotein J) and necrosismarkers (troponins). Although biomarkers provide utility for predicting cardiovascular risk, the identification and characterization of new biomarkers to achieve increasing diagnosis and prognostic efficiency in CVD prevention is of high clinical interest. In this review we will discuss on recently discovered biomarkers and their clinical applications. (C) 2012 Elsevier Ltd. All rights reserved.

引用

页码：S12 / S15

页数：4

共 38 条

[1]

Platelet-derived CD40L -: The switch-hitting player of cardiovascular disease [J].

André, P ;

Nannizzi-Alaimo, L ;

Prasad, SK ;

Phillips, DR .

CIRCULATION, 2002, 106 (08) :896-899

[2]

Serial bedside B-type natriuretic peptide strongly predicts prognosis in acute coronary syndrome independent of echocardiographic abnormalities [J].

Ang, Donald S. C. ;

Kong, Colin F. J. ;

Kao, Michelle P. C. ;

Struthers, Allan D. .

AMERICAN HEART JOURNAL, 2009, 158 (01) :133-140

[3]

Apple FS, 2002, CLIN CHEM, V48, P1097

[4]

Myeloperoxidase and plasminogen activator inhibitor 1 play a central role in ventricular remodeling after myocardial infarction [J].

Askari, AT ;

Brennan, ML ;

Zhou, XR ;

Drinko, J ;

Morehead, A ;

Thomas, JD ;

Topol, EJ ;

Hazen, SL ;

Penn, MS .

JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 197 (05) :615-624

[5]

Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework [J].

Atkinson, AJ ;

Colburn, WA ;

DeGruttola, VG ;

DeMets, DL ;

Downing, GJ ;

Hoth, DF ;

Oates, JA ;

Peck, CC ;

Schooley, RT ;

Spilker, BA ;

Woodcock, J ;

Zeger, SL .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (03) :89-95

[6]

A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia - A preliminary report [J].

Bar-Or, D ;

Lau, E ;

Winkler, JV .

JOURNAL OF EMERGENCY MEDICINE, 2000, 19 (04) :311-315

[7]

Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina [J].

Blankenberg, S ;

Tiret, L ;

Bickel, C ;

Peetz, D ;

Cambien, F ;

Meyer, J ;

Rupprecht, HJ .

CIRCULATION, 2002, 106 (01) :24-30

[8]

Biomarkers in acute myocardial infarction [J].

Chan, Daniel ;

Ng, Leong L. .

BMC MEDICINE, 2010, 8

[9]

Biomarkers of cardiovascular damage [J].

Collinson, Paul O. ;

Gaze, David C. .

MEDICAL PRINCIPLES AND PRACTICE, 2007, 16 (04) :247-261

[10]

Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care [J].

Cowie, MR ;

Struthers, AD ;

Wood, DA ;

Coats, AJS ;

Thompson, SG ;

PooleWilson, PA ;

Sutton, GC .

LANCET, 1997, 350 (9088) :1349-1353

← 1 2 3 4 →